Zygel is a small molecule commercialized by Zynerba Pharmaceuticals, with a leading Phase III program in Fragile X Syndrome. According to Globaldata, it is involved in 16 clinical trials, of which 12 were completed, 2 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Zygel’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Zygel is expected to reach an annual total of $157 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Cannabidiol (ZYN-002) is under development for the treatment of neuropsychiatric disorders including developmental epileptic encephalopathy in children and adolescents, Fragile X syndrome in children and adolescents, adult refractory focal seizures, pediatric autism spectrum disorder (ASD) (pervasive developmental disorder) and 22q11.2 deletion syndrome. It is applied transdermally as a gel. The drug candidate targets cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptors and also fatty acid amide hydrolase. It was also under development for the treatment of rheumatoid arthritis and knee pain due to osteoarthritis. It was under development for drug and alcohol addiction.
Zynerba Pharmaceuticals Overview
Zynerba Pharmaceuticals, formerly AllTranz, is a developer of next-generation synthetic cannabinoid therapeutics. The company produce transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company provides pipeline product candidates includes ZYN002. Its ZYN002 is a synthetic CBD, a non- cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery. Zynerba Pharmaceuticals’s ZYN002 is administered as a transdermal gel to children and adolescents with autism spectrum disorder. The company’s pipeline candidates target various indications which include refractory epileptic focal, fragile x syndrome, developmental and epileptic encephalopathies and autism spectrum disorder. Zynerba Pharmaceuticals is headquartered in Devon, Pennsylvania, the US.
The operating loss of the company was US$36.8 million in FY2021, compared to an operating loss of US$52.1 million in FY2020. The net loss of the company was US$37.3 million in FY2021, compared to a net loss of US$51.3 million in FY2020.
For a complete picture of Zygel’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.